Robust Expansion of Human Pluripotent Stem Cells: Integration of Bioprocess Design With Transcriptomic and Metabolomic Characterization
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Human embryonic stem cells (hESCs) have an enormous potential as a source for cell replacement therapies, tissue engineering, and in vitro toxicology applications. The lack of standardized and robust bioprocesses for hESC expansion has hindered the application of hESCs and their derivatives in clinical settings. We developed a robust and well-characterized bioprocess for hESC expansion under fully defined conditions and explored the potential of transcriptomic and metabolomic tools for a more comprehensive assessment of culture system impact on cell proliferation, metabolism, and phenotype. Two different hESC lines (feeder-dependent and feeder-free lines) were efficiently expanded on xeno-free microcarriers in stirred culture systems. Both hESC lines maintained the expression of stemness markers such as Oct-4, Nanog, SSEA-4, and TRA1-60 and the ability to spontaneously differentiate into the three germ layers. Whole-genome transcriptome profiling revealed a phenotypic convergence between both hESC lines along the expansion process in stirred-tank bioreactor cultures, providing strong evidence of the robustness of the cultivation process to homogenize cellular phenotype. Under low-oxygen tension, results showed metabolic rearrangement with upregulation of the glycolytic machinery favoring an anaerobic glycolysis Warburg-effect-like phenotype, with no evidence of hypoxic stress response, in contrast to two-dimensional culture. Overall, we report a standardized expansion bioprocess that can guarantee maximal product quality. Furthermore, the “omics” tools used provided relevant findings on the physiological and metabolic changes during hESC expansion in environmentally controlled stirred-tank bioreactors, which can contribute to improved scale-up production systems. Significance: The clinical application of human pluripotent stem cells (hPSCs) has been hindered by the lack of robust protocols able to sustain production of high cell numbers, as required for regenerative medicine. In this study, a strategy was developed for the expansion of human embryonic stem cells in well-defined culture conditions using microcarrier technology and stirred-tank bioreactors. The use of transcriptomic and metabolic tools allowed detailed characterization of the cell-based product and showed a phenotypic convergence between both hESC lines along the expansion process. This study provided valuable insights into the metabolic hallmarks of hPSC expansion and new information to guide bioprocess design and media optimization for the production of cells with higher quantity and improved quality, which are requisite for translation to the clinic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Energy Metabolism in Human Pluripotent Stem Cells and Their Differentiated Counterparts
Varum, S., Rodrigues, A. S., Moura, M. B., Momcilovic, O., Easley, C. A., Ramalho-Santos, J., Van Houten, B., & Schatten, G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020914 · Cited by 671
Self-citationSmith, J., Ladi, E., Mayer-Pröschel, M., & Noble, M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.170209797 · Cited by 399
Human pluripotent stem cell culture: considerations for maintenance, expansion, and therapeutics
Chen, K. G., Mallon, B. S., McKay, R. D. G., & Robey, P. G. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2013.12.005 · Cited by 358
Scalable Stirred-Suspension Bioreactor Culture of Human Pluripotent Stem Cells
Kehoe, D. E., Jing, D., Lock, L. T., & Tzanakakis, E. S. (2010) · Tissue Engineering Part A · doi:10.1089/ten.tea.2009.0454 · Cited by 264
Cited by
Correia, C., Koshkin, A., Duarte, P., Hu, D., Teixeira, A., Domian, I., Serra, M., & Alves, P. M. (2017) · Scientific Reports · doi:10.1038/s41598-017-08713-4 · Cited by 237
Self-citationProgress and challenges in large-scale expansion of human pluripotent stem cells
Kropp, C., Massai, D., & Zweigerdt, R. (2017) · Process Biochemistry · doi:10.1016/j.procbio.2016.09.032 · Cited by 167
Good Cell Culture Practice for stem cells and stem-cell-derived models
Pamies, D. (2016) · ALTEX · doi:10.14573/altex.1607121 · Cited by 160
“, mode of actions) underlying (toxicant) effects in a high-throughput manner, are also helping to expand current knowledge of PSC profiles, which has special relevance when PSC-derivatives are intended to be used for clinical applications (Silva et al., 2015).”
BackgroundMethodAbecasis, B., Aguiar, T., Arnault, É., Costa, R., Gomes-Alves, P., Aspegren, A., Serra, M., & Alves, P. M. (2017) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2017.01.004 · Cited by 100
Self-citationEnd-to-End Platform for Human Pluripotent Stem Cell Manufacturing
Pandey, P. R., Tomney, A., Woon, M. T., Uth, N., Shafighi, F., Ngabo, I., Vallabhaneni, H., Levinson, Y., Abraham, E., & Friedrich Ben-Nun, I. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010089 · Cited by 42
Metadata
- Authors
- Silva, M. M., Rodrigues, A. F., Correia, C., Sousa, M. F. Q., Brito, C., Coroadinha, A. S., Serra, M., & Alves, P. M.
- Venue
- Stem Cells Translational Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-05-15
- Volume
- 4
- Issue
- 7
- Pages
- 731-742
- ISSN
- 2157-6564 (ISSN-L)
- 2157-6580
- OpenAlex
- W2264267198
- Cited by
- 40
- References
- 5
- FWCI
- 2.44
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.